Skip to content

Blood Flow Restriction and High-intense Resistance Training in Aging: Interactions Between Neuroplasticity and Muscle

Resistance Training and Muscle - Brain Crosstalk

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05744167
Acronym
BRAIN-M
Enrollment
60
Registered
2023-02-24
Start date
2022-10-15
Completion date
2023-11-17
Last updated
2024-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Cognitive Decline, Frailty, Muscle Degeneration, Physical Disability, Sarcopenia

Keywords

Aging, Motor control, Cognitive function, Neuroplasticity, Brain health, Muscular fitness, Exerkines, Myokines, (Neuro)inflammation

Brief summary

BRAIN-M is a randomized controlled trial designed to examine the effects of a single bout or 12 weeks of blood-flow restriction training or high-intensity resistance training on cognitive function, brain health, muscular properties and physical performance in healthy older men 60-75 years old.

Detailed description

The BRAIN-M project is driven by the idea that understanding the mechanisms through which muscle and brain interact could offer new approaches to magnifying the beneficial and detrimental effects of exercise training on health at older age. Specifically, the investigators aim at identifying brain, blood, and muscle biomarkers that could serve as predictors of response to exercise training at either cognitive, brain, muscle or physical performance levels and study the associations between biomarkers in order to suggest a physiological model of brain-muscle and muscle-brain crosstalk in ageing. 60 male older adults (60-75y old) will be included in either 12 weeks of high-intense blood-flow restriction training (n = 20), muscle damaging resistance training (n = 20) or no exercise (n = 20). The control group will be asked to maintain their usual lifestyle.

Interventions

BEHAVIORALBFRT

Following a warm-up of 10 min, subjects in the experimental group will undergo BFRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). BFRT will be at 40% of 1 repetition maximum (1RM); The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.

BEHAVIORALMDRT

Following a warm-up of 10 min, subjects in the experimental group will undergo MDRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). The exercise will be at 80% of 1RM concentric-only or 120% of 1RM eccentric-only in a 3:1 ratio. The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.

Sponsors

Research Council of Lithuania
CollaboratorOTHER
Lithuanian University of Health Sciences
CollaboratorOTHER
Maastricht University
CollaboratorOTHER
Vrije Universiteit Brussel
CollaboratorOTHER
KU Leuven
CollaboratorOTHER
Wingate Institute
CollaboratorOTHER
Lithuanian Sports University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
60 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy male older adults * able to speak and read fluent Lithuanian * living in community during the study

Exclusion criteria

* cognitive and neurological disorders (e.g. dementia, stroke, Parkinson, multiple sclerosis) * previous lower extremity injury * diabetes mellitus type I or II * no oncologic disease * no bone fractures in the previous year * deep vein thrombosis * cardiovascular disorders (e.g. congestive heart failure, angina pectoris, uncontrolled arrhythmia, history of myocardial infarction or coronary bypass grafting in the past year) * obesity (BMI \>30kg/m²) * chronic fatigue, chronic headache, or chronic dizziness * ineligibility to MRI scanning (e.g. due to claustrofobia or metal implants) * The participants should not be engaged in any regular exercise programme during the previous 6 months (according to IPAQ), but able to perform 10 sit-ups * Any other consideration that interferes with the study aims and/or risk to the participant, at the discretion of the researcher

Design outcomes

Primary

MeasureTime frameDescription
Change in cognitive function on the Switching task (executive function)Before first exercise bout, immediately after first exercise bout, 1 hour after the first exercise bout and after the 12 week intervention periodThe switching task is a complex task where subjects need to switch (executive function) between a manikin task (visuospatial skill, attention and problem solving) and a mathematical computation task (mathematical computation skill, concentration and working memory).

Secondary

MeasureTime frameDescription
Changes in lactate levelsBefore first exercise bout, immediately after first exercise bout, 1 hour after the first exercise boutCapillary lactate levels will be measured in the acute exercise test.
Changes in blood serum levels of TNFalpha and syndecanBefore first exercise bout, immediately after first exercise bout, 1 hour after the first exercise boutWe will use enzyme-linked immunosorbent assays (ELISAs) to measure acute changes in TNFalpha, and syndecan before and after the first exercise bout.
Changes in blood plasma levels of BDNFBefore first exercise bout, immediately after first exercise bout, 1 hour after the first exercise bout and after the 12 week intervention periodWe will use enzyme-linked immunosorbent assays (ELISAs) to measure acute and chronic changes in BDNF before and after the first exercise bout; and after 12 weeks intervention
Changes in blood serum levels of IGF-1, IL-6 and kynurenineBefore and after the 12 week intervention periodWe will use enzyme-linked immunosorbent assays (ELISAs) to measure chronic changes in IGF-1, IL-6 and kynurenine before and after 12 weeks intervention
Changes in blood CK levelsBefore first exercise bout and every 3 weeks for a total of 7 times 48 hours after the eccentric-only training session in the MDRT group.Blood CK levels will be measured in the MDRT group 48 hours after each eccentric-only training session to assess the muscle damaging effect/repeated bout effect.
Changes in muscle contractile characteristics (with tensiomyography (TMG))Before and after the 12 week intervention periodMuscle involuntary contractile characteristics of the lower-limb muscles-the rectus femoris (RF), vastus medialis (VM), vastus lateralis (VL), biceps femoris (BF), semitendinosus (ST), tibialis anterior (TA), gastrocnemius medialis (GM) and gastrocnemius lateralis (GL)-will be recorded by measuring the response of these muscles to an induced electric stimulus (provoked by two self-adhesive electrodes) using TMG equipment on both the left and right lower extremities.
Changes in BMIBefore and after the 12 week intervention periodWeight and height will be combined to report BMI in kg/m\^2
Changes in body fat %Before and after the 12 week intervention periodbody fat % will be measured using bio-impedance analysis (Tanita)
Changes in SMIBefore and after the 12 week intervention periodSkeletal muscle mass index (SMI, kg/m\^2) will be measured using bio-impedance analysis (Tanita)
Changes in fat free massBefore and after the 12 week intervention periodFat free mass (kg) will be measured using bio-impedance analysis (Tanita)
Changes in patellar tendon crossectional areaBefore and after the 12 week intervention periodUltrasound will be used to assess the crossectional area (cm\^2) of the pattella tendon
Changes in patellar tendon stiffnessBefore and after the 12 week intervention periodWhile producing isometric knee extension force, ultrasound will be used to assess patellar tendon distension, which is a measure of tendon stiffness.
Changes in quadriceps muscle fascicle lengthBefore and after the 12 week intervention periodUltrasound will be used to quantify muscle geometrical properties such as fascicle length (cm).
Changes in quadriceps muscle fascicle angleBefore and after the 12 week intervention periodUltrasound will be used to quantify muscle geometrical properties such as fascicle angle (°).
Changes in quadriceps muscle thicknessBefore and after the 12 week intervention periodUltrasound will be used to quantify muscle geometrical properties such as quadriceps muscle thickness.
Changes in quadriceps muscle cross-sectional areaBefore and after the 12 week intervention periodMRI will be used to measure muscle cross-sectional volume changes of the quadriceps muscles
Change in cognitive function on the 2-Choice Reaction time (processing speed), Go/No-Go (inhibition) or 6 letter Memory Search (memory) testBefore first exercise bout, immediately after first exercise bout, 1 hour after the first exercise bout and after the 12 week intervention periodCognitive functioning will be assessed with the Automated Neuropsychological Assessment Metrics 4 (ANAM4) cognitive test battery, testing several cognitive domains.
Changes in quadriceps muscle intramuscular fatBefore and after the 12 week intervention periodH-MRS (proton magnetic resonance spectroscopy) will be used to measure intramuscular fat in the quadriceps muscle
Changes in brain gray matter volume (with magnetic resonance imaging)Before and after the 12 week intervention periodMRI will be used to measure changes in gray matter volume using T1 images
Changes in brain white matter volume (with magnetic resonance imaging)Before and after the 12 week intervention periodMRI will be used to measure changes in white matter integrity using DTI sequence
Changes in brain neural integrity (with proton magnetic resonance spectroscopy)Before and after the 12 week intervention periodH-MRS will be used to measure changes in N-acetylaspartate levels in specific brain regions: right dorsolateral prefrontal cortex, left hippocampus and left primary sensorimotor cortex.
Changes in brain neuroinflammation (with proton magnetic resonance spectroscopy)Before and after the 12 week intervention periodH-MRS will be used to measure changes in myo-inositol levels in specific brain regions: right dorsolateral prefrontal cortex, left hippocampus and left primary sensorimotor cortex.
Changes in brain neuroplasticity marker (with proton magnetic resonance spectroscopy)Before and after the 12 week intervention periodH-MRS will be used to measure changes in Glx in specific brain regions: right dorsolateral prefrontal cortex, left hippocampus and left primary sensorimotor cortex.
Changes in balance (with posturography on Kistler platform)Before and after the 12 week intervention periodBalance will be assessed in four different positions (two legs stance vs Romberg stance with eyes open vs closed) with or without a cognitive task to measure dual task effects.
Changes in handgrip strengthBefore and after the 12 week intervention periodHandgrip strength will be measured using Jamar dynamometry
Changes in maximal isometric strength (with Biodex)Before and after the 12 week intervention periodKnee extension/flexion maximal isometric strength (N) will be measured using Biodex.
Changes in isokinetic peak torque (with Biodex)Before and after the 12 week intervention periodKnee extension/flexion isokinetic peak torque measurements will be done at 60°/s
Changes in rate of force development (with Biodex)Before and after the 12 week intervention periodRate of force development will be measured during maximal knee extension/flexion movement.
Changes in physical performance (with the Fitness Fullerton Test battery for the Senior)Before and after the 12 week intervention periodDetermination of motor control tasks relevant to daily life activities. A selection of tests, including the sit-to-stance test, timed up-and-go test, and other physical tests
Changes in subjective quality of life (patient reported outcome questionnaires)Before and after the 12 week intervention periodQuality of life will be assessed using the World Health Organisation 100 (WHO 100) questionnaire
Changes in nutrition (patient reported outcome questionnaires)Before and after the 12 week intervention periodWe will use a selection of patient reported outcome measures to evaluate their nutrition (using the Actual nutrition registration questionnaire).
Changes in subjective sleep quality (patient reported outcome questionnaires)Before and after the 12 week intervention periodWe will use a selection of patient reported outcome measures to evaluate their quality of sleep (using the Stanford sleep quality scale).
Changes in reported physical activity levels (patient reported outcome questionnaires)Before and after the 12 week intervention periodWe will assess physical activity levels using the International Physical Activities Questionnaire (IPAQ)
Changes in quadriceps muscle fiber typeBefore and after the 12 week intervention periodH-MRS (proton magnetic resonance spectroscopy) will be used to measure fiber type in the quadriceps muscle

Countries

Lithuania

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 28, 2026